Use of CSF biomarkers in Alzheimer’s disease clinical trials

被引：0
|
作者：
K. Blennow
H. Zetterberg
机构：
[1] the Sahlgrenska Academy at Göteborg University,Clinical Neurochemistry Laboratory
[2] The Sahlgrenska Academy at Göteborg University,Clinical Neurochemistry Lab
[3] Sahlgrenska University Hospital,undefined
来源：
JNHA - The Journal of Nutrition, Health and Aging | 2009年 / 13卷
关键词：
Mild Cognitive Impairment; Lewy Body Dementia; BACE1 Inhibitor; Secretase Inhibitor; Mild Cognitive Impairment Case;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Alzheimer's Disease and the Routine Clinical Use of CSF Biomarkers
    Martorana, Alessandro
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2017, 16 (04) : 407 - 413
  • [2] Use of CSF biomarkers in the diagnosis of Alzheimer's disease in clinical practice
    Koric, L.
    Felician, O.
    Ceccaldi, M.
    REVUE NEUROLOGIQUE, 2011, 167 (6-7) : 474 - 484
  • [3] Alzheimer's disease CSF biomarkers: clinical indications and rational use
    Niemantsverdriet, Ellis
    Valckx, Sara
    Bjerke, Maria
    Engelborghs, Sebastiaan
    ACTA NEUROLOGICA BELGICA, 2017, 117 (03) : 591 - 602
  • [4] Insights into the use of biomarkers in clinical trials in Alzheimer's ' s disease
    Pascoal, Tharick A.
    Aguzzoli, Cristiano S.
    Lussier, Firoza Z.
    Crivelli, Lucia
    Suemoto, Claudia K.
    Fortea, Juan
    Rosa-Neto, Pedro
    Zimmer, Eduardo R.
    Ferreira, Pamela C. L.
    Bellaver, Bruna
    EBIOMEDICINE, 2024, 108
  • [5] Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
    Leuzy, Antoine
    Bollack, Ariane
    Pellegrino, Daniela
    Teunissen, Charlotte E.
    La Joie, Renaud
    Rabinovici, Gil D.
    Franzmeier, Nicolai
    Johnson, Keith
    Barkhof, Frederik
    Shaw, Leslie M.
    Arkhipenko, Alexander
    Schindler, Suzanne E.
    Honig, Lawrence S.
    Moscoso Rial, Alexis
    Scholl, Michael
    Zetterberg, Henrik
    Blennow, Kaj
    Hansson, Oskar
    Farrar, Gill
    ALZHEIMERS & DEMENTIA, 2025, 21 (03)
  • [6] Clinical indications for analysis of Alzheimer's disease CSF biomarkers
    Engelborghs, S.
    REVUE NEUROLOGIQUE, 2013, 169 (10) : 709 - 714
  • [7] Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting
    Dumurgier, Julien
    Vercruysse, Olivier
    Paquet, Claire
    Bombois, Stephanie
    Chaulet, Chloe
    Laplanche, Jean-Louis
    Peoc'h, Katell
    Schraen, Susanna
    Pasquier, Florence
    Touchon, Jacques
    Hugon, Jacques
    Lehmann, Sylvain
    Gabelle, Audrey
    ALZHEIMERS & DEMENTIA, 2013, 9 (04) : 406 - 413
  • [8] Fluid biomarkers in clinical trials of Alzheimer's disease therapeutics
    Ritter, Aaron
    Cummings, Jeffrey
    FRONTIERS IN NEUROLOGY, 2015, 6
  • [9] Use of Biomarkers in Clinical Trials of Alzheimer Disease From Concept to Application
    Wu, Liyong
    Rosa-Neto, Pedro
    Gauthier, Serge
    MOLECULAR DIAGNOSIS & THERAPY, 2011, 15 (06) : 313 - 325
  • [10] The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials
    Olsson, Bob
    Schott, Jonathan M.
    Blennow, Kaj
    Zetterberg, Henrik
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2017, 17 (08) : 767 - 775
12345